Contact Us

AMR Diagnostic

OVM has developed a simple diagnostic test for Anti-Microbial Resistance (AMR)
Rapid, effective testing for Anti-Microbial Resistance

AMR Diagnostic Test

Cultured patient samples – 100% PCR-LFIA match for KPC2

Cultured patient samples – 100% PCR-LFIA match for KPC2 expression. The circles in each petri dish represent IMI, MRP and ETP.

Oxford Vacmedix had developed a simple diagnostic test for Anti-Microbial Resistance (AMR). The basic research for this test was done alongside the ROP technology development in Professor Shisong Jiang’s lab at the University of Oxford. The test, which is an easy-to-use Lateral Flow Immuno Assay (LFIA) strip, measures resistance to carbapenems, a class of antibiotics commonly used in severely ill patients.
OVM was invited to join this project, with the funding to develop the AMR diagnostic provided by Innovate UK . The project was done in collaboration with Imperial College, London and the prestigious Ditan Infectious Diseases hospital in Beijing, China. The core technology of the test has been patented by OVM and tested by Changzhou Biotech in China.
GAD logo_400x400
Photo page 33

AMR LFIA: inexpensive, simple and quick

The test is currently in clinical testing. Initial results show 100% concordance with standard PCR tests to detect anti-microbial resistance to KPC2 bacteria. Over 2000 test strips have been produced and data is being collected. Further work to detect AMR to all strains of carbapenemase bacteria is planned with the aim of achieving regulatory approval for the test.

The LFIA test is simple to use and require only a sputum sample. It is inexpensive to produce, and results are delivered in approximately 20 minutes and read with a Cube reader. The AMR test will fulfil a real need in a growing market. OVM is looking for partners to commercialise the kit.

The AMR test will fulfil a real need in a growing market. OVM is looking for partners to commercialise the kit.
AMR Test Packaging
Photo page 33
The LFIA test is read by a Cube reader, produced by GA Diagnostics.

OVM licenced rights to develop and commercialise ROP-based diagnostics for certain indications to Changzhou Biotech (CBIG) in China and receives milestones/royalties on all ROP-based diagnostic tests developed by CBIG.

CBIG has developed an ELISPOT diagnostic test for TB which has regulatory approval from the NPMA in China. The test is fast, accurate and very cost-competitive and is one of only two proprietary TB-ELISPOT kits with global freedom to operate. The CBIG TB test has significant cost advantages arising from production of the recombinant assay.

Latent tuberculosis (LTBI) is a global issue with approximately 2bn latent TB infections globally, according to the WHO. There is huge need for fast, accurate and affordable diagnostic tests for latent TB infections.
Diagnostic Packaging
en_GBEnglish
en_GBEnglish